Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. ASCO Meeting Abstracts. - Peeters, M (J Clin Oncol, 2011)
et al.